TNFRSF1A and type 2 diabetes mellitus: In clinical studies of SGLT2 inhibitors in individuals with T2DM, similar effects on urine IL-6 and MCP-1, as well as serum tumor necrosis factor receptor 1 (TNFR1) and IL-6, were reported [49].